Pharma & Biotech Global Week in Review 26 January 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

WHO R&D financing committee approved with controversial industry expert (IP Watch) (KEI) (KEI) (KEI)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.


GSK critiques Anti-Counterfeiting Trade Agreement (IP Watch)

WHO Members show dismay at delay on Counterfeit Medicines Group (IP Watch)

WHO R&D financing committee approved with controversial industry expert (IP Watch) (KEI) (KEI) (KEI)

BioCentury this week explores orphan drugs with HP&M attorney and NORD Board Chair (FDA Law Blog)

EU: Paediatric extensions and transitional provisions: a question of timing (The SPC Blog)

India: Patent Office continue refusing pharmaceutical formulations under S.3 (d) and (e) (Patent Circle)

Turkey: Turkish legislation on GMOs and the Biosafety Council takes effect (jiplp)

US: Stanford v Roche: the US Bayh-Dole Act and inventors’ rights (IP Osgoode)

US: ‘Importance of new companies for drug discovery: origins of a decade of new drugs’ the Kneller Study (PatentlyBIOtech)

US: The nexus between biotechnology and economic recovery (Patent Docs)

US: Reports detail FDA’s 505(q) citizen petition response track record; Section 505(q) may have some unintended consequences, FDA says (Part I – FDA Law Blog) (Part II – FDA Law Blog)

US: Tussle over BPCIA ‘market’ versus ‘data’ exclusivity continues; this time the generic supporters chime in (FDA Law Blog)

US: FDA releases plan intended to improve the 510(k) program; plan contains 25 action items to implement during 2011 (FDA Law Blog)

US: Genetic Technologies files patent infringement suit against American Esoteric Laboratories over genetic testing services (Patent Docs)


Actos (Pioglitazone) – US: Takeda files patent infringement complaint against Cadila following Para IV certification filing (Patent Docs)

Antara (Fenofibrate) – US: NJ District Court declines to exercise declaratory judgment jurisdiction in feud over generic Antara; Lupin is given another bite at the apple (FDA Law Blog)

Caduet (Atorvastatin, Amlodipine) – US: Mylan enters into settlement agreement with Pfizer over Caduet (SmartBrief)

Cervarix and Gardasil – EU: Fifth referral on the scope of the SPC Regulation for combination products: University of Queensland and CSL (C-630/10) (Kluwer Patent Blog)

Effexor (Venlafaxine) – US: Aurobindo Pharma settles with Wyeth in Effexor XR litigation (Patent Docs)

Epipen (Epinephrine) – US: King Pharmaceuticals files patent infringement suit against Intelliject following Para IV certification filing (Patent Docs)

Escitalopram – Norway: Borgarting Appelate Court finds ratiopharm’s product manufactured by alternative process, not infringing Lundbeck’s process patent (Kluwer Patent Blog)

Fentanyl – Austria: Supreme Court holds that if someone exports goods from Germany and it is not proven that same person imported them into Austria, there is no infringement of patent rights in Austria (Kluwer Patent Blog)

Gemzar (Gemcitabine) – US: Eli Lilly files new 337 complaint regarding Certain Gemcitabine (ITC Law Blog)

Lipitor (Atorvastatin) – US: Mylan announces settlement agreement with Pfizer concerning Lipitor (SmartBrief)

 Lotronex (Alosetron) – US: Prometheus files patent infringement complaint against Roxane following Para IV certification (Patent Docs)

Nebilet (Nebivolol) – Italy: Enantiomer patent case decided in Italy: Janssen-Menarini v EG (Kluwer Patent Blog)

Prandin (Repaglinide) – US: Novo’s Prandin patent found invalid: Novo Nordisk v Caraco (Patent Docs)

Provigil (Modafinil) – US: Accessing brand-generic settlement data: FTC v. Cephalon (Patently-O)

Seroquel (Quetiapine) – UK: Teva launches High Court action to revoke AstraZeneca’s European patent (IP Factor)

Synagis – US: PDL BioPharma Synagis patent invalidated: Medimmune v PDL BioPharma (Patent Docs)

Tarka (Trandolapril, Verapamil) – US: Glenmark loses jury verdict in DNJ over Tarka (IPBiz)

Wechol (Colesevelam) – US: Watson confirms Welchol oral suspension patent challenge (SmartBrief)

%d bloggers like this: